Dr. Reddy’s Receives Positive CHMP Opinion for AVT03 Biosimilar
Dr. Reddy’s Laboratories has received a positive opinion from the European Medicines Agency’s CHMP for marketing authorization of AVT03, a biosimilar of Prolia® and Xgeva®. This approval could enhance their presence in the European biosimilars market. Analysts rate RDY stock as a Buy with a $16.00 price target, citing strong financial health despite challenges in the U.S. generics market. The company, established in 1984, focuses on affordable medicines across various therapeutic areas and has a market cap of $12.51B.
Dr Reddy’s Laboratories ( (RDY) ) has shared an update.
On September 22, 2025, Dr. Reddy’s Laboratories announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for AVT03, a biosimilar of Prolia® and Xgeva®, in European markets. This development is a significant step for Dr. Reddy’s as it strengthens their position in the biosimilars market, potentially expanding their reach in Europe and the UK, and offering new treatment options under the tradenames Acvybra® and Xbonzy® upon approval.
The most recent analyst rating on (RDY) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
Dr Reddy’s Laboratories exhibits strong financial health and strategic growth initiatives, which are offset by challenges in the U.S. generics market and declining gross profit margins. The technical analysis suggests stability, while the valuation is fair. The earnings call provided a mixed outlook, balancing growth with market challenges.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India, established in 1984. The company is committed to providing access to affordable and innovative medicines, offering a portfolio that includes APIs, generics, branded generics, biosimilars, and OTC products. Their major therapeutic areas include gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology, with primary markets in the USA, India, Russia & CIS countries, China, Brazil, and Europe. Dr. Reddy’s is known for its robust capabilities in the development, manufacture, and commercialization of biosimilar products, particularly in oncology and immunology.
Average Trading Volume: 1,205,021
Technical Sentiment Signal: Strong Buy
Current Market Cap: $12.51B
For an in-depth examination of RDY stock, go to TipRanks’ Overview page.
